CIIE Stories | For health, for all: an esteemed pharmaceutical company dedicated to health at CIIE

At the China International Import Expo (CIIE), the array of meticulously designed booths dazzled visitors, but one bright pink display added a unique vitality to the vast venue—it came from the multinational pharmaceutical company Organon. This lively pink not only caught the eye but also vividly illustrated the company's unique vision of focusing on the health of women and their families. 

A STRONG START AND ACCELERATED PROGRESS

In its second year since establishment, Organon made its appearancedebut at the fifth CIIE. Having participated for several consecutive years, this global pharmaceutical company has deeply felt the ongoing "spillover effects" of the CIIE over the past three years. 

Their first "CIIE Baby", ATOZET®, made a remarkable entry into the Chinese market. After its debut at the CIIE in November 2022, it received official approval in China by September 2023 and was commercially launched in 2024, swiftly becoming part of the national medical insurance catalog. These milestones underscore the vital role of the CIIE in speeding up the introduction of innovative medicines to benefit patients. As the world's first national-level expo dedicated to imports, the CIIE provides multinational pharmaceutical companies with a critical platform to understand the Chinese market and explore new collaboration opportunities. It also facilitates the quicker introduction of global innovative drugs and advanced health solutions to China, ultimately benefiting more patients. 

"The rapid introduction of ATOZET® would not have been possible without the CIIE, an international platform for exchange and cooperation," said Knightley Wei, Vice President and Head of Medical Affairs & Outcomes Research at Organon China. "We are also delighted to see this excellent product and the new trend in lipid health management it represents being increasingly recognized and understood through the CIIE." 

FROM WOMEN'S HEALTH TO FAMILY HEALTH

At the eighth CIIE, Organon's booth theme expanded from focusing on "her" to "her family", highlighting not only the health protection across the full reproductive cycle of women but also showcasing global experiences and innovative practices in lipid management. 

"Currently, public awareness of lipid disorders, the 'silent health killer', is still insufficient," Wei noted. Cardiovascular disease has become one of the leading causes of death among urban and rural residents in China, yet the awareness, treatment, and control rates of lipid disorders among Chinese adults are only as low as 11.7%, 10.1%, and 4.8%, respectively. "Facing these 'three lows', we hope to collaborate with various parties to explore more possibilities in comprehensive cardiovascular disease management. Leveraging the CIIE's 'magnetic effect', we aim to spread the scientific concept of lipid management to more people, jointly addressing this increasingly severe public health challenge."

In 2024, building on their involvement with the CIIE, Organon partnered with the China Cardiovascular Health Alliance to launch the "Lipid Test Optimization" project. This initiative, developed in collaboration with industry stakeholders, aims to improve lipid health management. The project has already been implemented in hundreds of hospitals across the country. At this year's CIIE, Organon will showcased the widely recognized "optimized lipid test report" at their booth. Organon hopes to leverage the CIIE to turn health initiatives into public action, increase public awareness about health, and help more people understand the importance and urgency of managing lipid levels. This effort aligns with the broader goal of advancing the Health China 2030 Initiative. 

“ROOTED IN CHINA, BENEFITING CHINA, AND IMPACTING THE WORLD”

The CIIE acts as a massive "magnet", continuously attracting top participants from the global industrial chain and building an efficient, open ecosystem for exchange and cooperation. With the support of this national platform, Organon has established close partnerships with several local biotechnology companies, jointly exploring innovative paths for drug development and market entry.

Zafer Unluer, President of Organon China, stated, "China, as Organon's second-largest global market, is of significant importance to us. We aim to provide innovative and high-quality health solutions for more women and their families, actively contributing to the realization of the Health China 2030 blueprint. Through this open, cooperative platform, we look forward to accelerating the introduction of more innovative products, aligning global innovation with China's needs. We also anticipate collaborating with more outstanding local partners to create more win-win cooperation models, bringing China's innovative achievements to the world and promoting sustainable innovation and development in the global healthcare industry."

In September 2025, Organon, in partnership with the leading local biopharmaceutical company Henlius, successfully launched the first "China-originateddeveloped" Denosumab to the international market. Through cooperation between the two partiesBy leveraging Organon's strong global commercialization capabilities, the Denosumab biosimilar HLX14, available in two specifications (60mg/ml and 120mg/1.7ml), received approval for market entry in both the United States and the European Union. This achievement effectively creates a bridge for Chinese innovative drugs to reach global markets. It not only showcases the integration of resources and complementary strengths but also underscores the significant value of the CIIE as a platform for global cooperation. The CIIE facilitates collaboration between multinational pharmaceutical companies and Chinese innovators, fostering the exchange of technology, market access, and resources. This collaboration injects new momentum into the optimization and advancement of the global pharmaceutical industry.